These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22403077)

  • 1. Phosphoinositide 3-kinases in health and disease.
    Ghigo A; Morello F; Perino A; Hirsch E
    Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Ks-drug targets in inflammation and cancer.
    Wymann M
    Subcell Biochem; 2012; 58():111-81. PubMed ID: 22403076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoinositide 3-kinases-a historical perspective.
    Toker A
    Subcell Biochem; 2012; 58():95-110. PubMed ID: 22403075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The essential role of phosphoinositide 3-kinases (PI3Ks) in regulating pro-inflammatory responses and the progression of cancer.
    Chen K; Iribarren P; Gong W; Wang JM
    Cell Mol Immunol; 2005 Aug; 2(4):241-52. PubMed ID: 16274621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K signalling in inflammation.
    Hawkins PT; Stephens LR
    Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in subunits of PI3K class I in cancer.
    Cui W; Cai Y; Zhou X
    Pathology; 2014 Apr; 46(3):169-76. PubMed ID: 24614719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
    Valet C; Severin S; Chicanne G; Laurent PA; Gaits-Iacovoni F; Gratacap MP; Payrastre B
    Adv Biol Regul; 2016 May; 61():33-41. PubMed ID: 26714793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods to measure the enzymatic activity of PI3Ks.
    Ciraolo E; Gulluni F; Hirsch E
    Methods Enzymol; 2014; 543():115-40. PubMed ID: 24924130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
    Katso R; Okkenhaug K; Ahmadi K; White S; Timms J; Waterfield MD
    Annu Rev Cell Dev Biol; 2001; 17():615-75. PubMed ID: 11687500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging mechanisms of isoform-specific PI3K signalling.
    Vanhaesebroeck B; Guillermet-Guibert J; Graupera M; Bilanges B
    Nat Rev Mol Cell Biol; 2010 May; 11(5):329-41. PubMed ID: 20379207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives.
    Vyas P; Vohora D
    Curr Drug Targets; 2017; 18(14):1622-1640. PubMed ID: 27739372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the potential of PI3K inhibitors for inflammation and cancer.
    Crabbe T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):253-6. PubMed ID: 17371252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
    Foster JG; Blunt MD; Carter E; Ward SG
    Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
    Ghigo A; Hirsch E
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of phospholipase C beta, gamma, and delta families alters cell growth and phosphatidylinositol 4,5-bisphosphate levels.
    Nebigil CG
    Biochemistry; 1997 Dec; 36(50):15949-58. PubMed ID: 9398329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinases as targets for therapeutic intervention.
    Wetzker R; Rommel C
    Curr Pharm Des; 2004; 10(16):1915-22. PubMed ID: 15180528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
    Gabelli SB; Mandelker D; Schmidt-Kittler O; Vogelstein B; Amzel LM
    Biochim Biophys Acta; 2010 Mar; 1804(3):533-40. PubMed ID: 19962457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.